Related Experiment Video
Updated: Jun 25, 2026
10:26
Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
[Botulinum toxin in nonneurogenic bladder dysfunction]
1Neurourologie, Spinal Cord Injury Center, Uniklinik Balgrist, Zürich, Schweiz.
Der Urologe. Ausg. A
|February 6, 2009
Summary
Botulinum toxin type A injections offer a minimally invasive treatment for overactive bladder when other therapies fail. This option shows favorable efficacy for up to 31 weeks but may require self-catheterization due to potential urinary retention.
Area of Science:
- Urology
- Pharmacology
- Minimally Invasive Procedures
Context:
- Nonneurogenic overactive bladder (OAB) significantly impacts quality of life.
- Traditional treatments include anticholinergic drugs and surgery.
- Limited options exist for patients unresponsive or intolerant to anticholinergics.
Purpose:
- To review the efficacy and safety of intradetrusor botulinum toxin type A injections for OAB.
- To summarize current data on dosages, adverse events, and injection techniques.
- To provide an overview of this alternative therapy over the past six years.
Summary:
- Intradetrusor botulinum toxin type A demonstrates favorable initial efficacy for OAB symptoms, starting around day 4 post-injection.
- Therapeutic effects can persist for up to approximately 31 weeks.
- Potential adverse events include elevated postvoid residual volumes, possibly necessitating clean intermittent self-catheterization.
Impact:
- Botulinum toxin type A offers a viable, minimally invasive alternative for refractory OAB patients.
- Understanding efficacy and potential side effects guides clinical decision-making.
- This review highlights an important off-label treatment option in urology.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...